Table 1.
Clinical parameters and molecular characteristics of the ALL cases included in the study.
| Laboratory ID | Subtype | Sex | Age at Sample Collection | Diagnosis | Age at Diagnosis | Sample Type | Cytogenetic Aberrations | Survival | Xeno | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ph+ | MLL | p16 | Other | Condition | Days Since dx | ||||||||
| 0054 | pro B-ALL | f | 70 | initial | 70 | bone marrow | dead | 358 | ✓ | ||||
| 0054 | pro B-ALL | f | 71 | relapse | 70 | blood | dead | 358 | |||||
| 0072 | pro B-ALL | m | 63 | initial | 63 | blood | near tetraploid | dead | 77 | ||||
| 0122 | pro B-ALL | m | 47 | initial | 47 | blood | +X, −, +21 | unknown | 2018 | ✓ | |||
| 0130 | pro B-ALL | f | 18 | initial | 18 | bone marrow | del(12)(p13) | dead | 160 | ||||
| 0134 | pro B-ALL | m | 43 | initial | 43 | bone marrow | +22 | dead | 205 | ✓ | |||
| 0152 | pro B-ALL, biphenotypic | f | 52 | initial | 52 | blood | dead | 66 | ✓ | ||||
| 0210 | pro B-ALL, biphenotypic | m | 67 | initial | 67 | bone marrow | del(6)(p21p25), ins(2;6)(p22;?p22?p23?), r(6)(p12q13), dic(16;17)(q11;p11) | alive | 237 | ||||
| 0012 | common B-ALL | f | 77 | relapse | 76 | blood | dead | 285 | |||||
| 0031 | common B-ALL | f | 37 | initial | 37 | unknown | IGH rearrangement | dead | 1186 | X | |||
| 0043 | common B-ALL | f | 40 | initial | 40 | blood | dead | 81 | ✓ | ||||
| 0062 | common B-ALL | m | 21 | initial | 21 | blood | del(6)(q?16q23), +19, add(20)(p) | alive | 4155 | ||||
| 0065 | common B-ALL | f | 20 | initial | 20 | blood | unknown | 4 | |||||
| 0071 | common B-ALL | m | 73 | initial | 73 | blood | dead | 12 | |||||
| 0082 | common B-ALL | m | 63 | initial | 63 | bone marrow | inv(3)(p21;q26), der(7;8)(q10;q10), del(7)(q22), del(13)(q14q31), −14, −15, −Y | alive | 3713 | ||||
| 0100 | common B-ALL | m | 42 | initial | 42 | bone marrow | +der(5), −22, +der(22)x2 | alive | 3457 | ||||
| 0125 | common B-ALL | f | 75 | initial | 75 | blood | unknown | - | |||||
| 0147 | common B-ALL | f | 55 | initial | 55 | blood | +6, +8, +11, +14, +21, +22 | unknown | 1784 | ||||
| 0154 | common B-ALL | m | 78 | initial | 78 | blood | +1, del(6)(q21q23), del(11)(q21q23), +19, +21, +21 | dead | 79 | ||||
| 0161 | common B-ALL | m | 23 | initial | 23 | bone marrow | +6, +11, +14, +21, +21 | unknown | 1853 | ||||
| 0168 | common B-ALL | f | 78 | initial | 78 | blood | −4, −7, −9, t(12;17)(q24;q21), −17, +mar | alive | 1997 | ||||
| 0183 | common B-ALL | f | 59 | initial | 59 | bone marrow | dead | 1396 | |||||
| 0188 | common B-ALL | f | 80 | relapse | 78 | blood | t(4;9)(p15;q21), −4, −7, −9, t(12;17)(q24;q12), −17, +mar | alive | 1994 | ||||
| 0202 | common B-ALL | m | 36 | initial | 36 | bone marrow | unknown | 343 | ✓ | ||||
| 0207 | common B-ALL | m | 46 | initial | 46 | bone marrow | unknown | 959 | |||||
| 0212 | common B-ALL | f | 62 | relapse | 62 | bone marrow | alive | 172 | ✓ | ||||
| 0213 | common B-ALL | m | 53 | initial | 53 | bone marrow | alive | 44 | |||||
| P67 | common B-ALL | m | 18 | initial | 18 | bone marrow | alive | 5180 | ✓ | ||||
| P74 | common B-ALL | f | 76 | initial | 76 | unknown | unknown | 287 | |||||
| 0141 | common B-ALL, biphenotypic | m | 43 | initial | 43 | bone marrow | +21 | alive | 2880 | ✓ | |||
| P33 | pre-B-ALL | m | 28 | initial | 28 | unknown | unknown | 274 | ✓ | ||||
| 0094 | mature B-ALL | f | 85 | relapse | 84 | blood | dead | 226 | ✓ | ||||
| 0074 | B-ALL, not further specified | m | 31 | initial | 31 | blood | del(1)(q23), del(12)(p13), +21 | dead | 35 | ✓ | |||
| 0138 | B-ALL, not further specified | f | 49 | initial | 49 | bone marrow | der(15), MYC rearrangement, TCF3 deletion | dead | 46 | ||||
| 0151 | B-ALL, not further specified | m | 84 | initial | 84 | blood | dead | 97 | ✓ | ||||
| 0159 | B-ALL, not further specified | f | 74 | initial | 74 | bone marrow | unknown | - | ✓ | ||||
| 0200 | B-ALL, not further specified | f | 37 | initial | 37 | blood | unknown | 5 | ✓ | ||||
| 0204 | B-ALL, not further specified | m | 20 | initial | 20 | blood | CRLF2 and IGH rearrangement | alive | 724 | ||||
| P21 | B-ALL, not further specified | f | 76 | relapse | 75 | blood | unknown | 2 | |||||
| P11 | B-ALL, not further specified | f | 22 | relapse | 19 | bone marrow | dead | 1384 | |||||
| P25 | pre T-ALL | m | 22 | initial | 22 | bone marrow | add(3)(q), del(7)(q31), +21 | unknown | 3561 | ||||
| 0019 | T-ALL, not further specified | m | 26 | initial | 26 | bone marrow | unknown | 2933 | ✓ | ||||
| 0070 | T-ALL, not further specified | m | 43 | initial | 43 | blood | unknown | 2094 | |||||
| 0170 | T-ALL, not further specified | f | 57 | initial | 57 | bone marrow | alive | 1890 | ✓ | ||||
m, male; f, female. Cytogenetics: red fields indicate a positive result of the analysis, while grey fields indicate absence of the respective aberration. Fields were left white when no analysis was conducted, or the result is unknown. Ph+, BCR::ABL1-positive; MLL, KMT2A rearrangement. Survival: days after diagnosis are calculated with either the date of death or the last day of contact. Unknown condition was stated for samples where the last contact was more than twelve months ago. Xeno: red fields indicate samples that were subsequently xenografted into NSG mice for further evaluation. Arrows indicate successful engraftment and crosses failed attempts of in vivo tumor cell proliferation.